Buy Recommendation for Anavex Life Sciences: Promising Alzheimer's Treatment and Expanding Clinical Pipeline

TipRanksNov 27 06:25 ET

Anavex Submits Marketing Authorization Application to EU Regulator for Blarcamesine to Treat Alzheimer's; Shares Jump Pre-Bell

MT NewswiresNov 26 09:29 ET

Express News | Anavex Life Sciences Announces Submission of Blarcamesine Maa for Treatment of Alzheimer’s Disease to EMA

ReutersNov 26 07:30 ET

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow JonesNov 25 09:15 ET · Ratings

Anavex Life Sciences Price Target Maintained With a $46.00/Share by D. Boral Capital

Dow JonesNov 25 09:15 ET · Ratings

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal

GlobeNewswireNov 25 07:30 ET